Interviews with local companies in Massachusetts and how they have responded to the pandemic. Watch now!
High performance, point-of-care rapid test for the detection of Influenza A&B The test utilizes traditional lateral flow technology with performance near or exceeding sensitivity of other reader-based tests without [...]
New to the Burlington, MA business community, Sekisui Diagnostics comes equipped to contribute to the ongoing effort against COVID-19. Watch now!
Doctor David B. Sacks selected to receive the 2020 IFCC Distinguished Award for Laboratory Medicine and Patient Care Read Full Press Release
Sekisui Diagnostics announced today an agreement with Mesa Biotech to distribute their Accula™ SARS-Cov-2 Test which received Emergency Use Authorization (EUA) on March 23, 2020. The Accula™ SARS-CoV-2 Test [...]
SEKISUI CHEMICAL CO. LTD. was once again recognized as one of the ‘Most Sustainable Corporations in the World’ in Corporate Knights, 2020 Global 100 Index ranking 12th (out of [...]
Burlington, MA, USA– 25th November 2019 – Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing [...]
Click here for full story
Burlington, MA – October 8, 2019 –Sekisui Diagnostics announces the Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the US Food and Drug [...]
Sekisui Diagnostics, LLC announces today the launch of the Silaris RSV Test, the newest assay on their molecular, point-of-care (POC) system. Silaris is an affordable, CLIA Waived, polymerase chain [...]